BR112015022974A8 - composição terapêutica para tratar um tumor ou patógeno, composição de vacina e uso - Google Patents
composição terapêutica para tratar um tumor ou patógeno, composição de vacina e uso Download PDFInfo
- Publication number
- BR112015022974A8 BR112015022974A8 BR112015022974A BR112015022974A BR112015022974A8 BR 112015022974 A8 BR112015022974 A8 BR 112015022974A8 BR 112015022974 A BR112015022974 A BR 112015022974A BR 112015022974 A BR112015022974 A BR 112015022974A BR 112015022974 A8 BR112015022974 A8 BR 112015022974A8
- Authority
- BR
- Brazil
- Prior art keywords
- pathogen
- tumor
- immunotherapy
- infected
- apoptosis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 244000052769 pathogen Species 0.000 title abstract 5
- 230000001717 pathogenic effect Effects 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 230000000735 allogeneic effect Effects 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 230000017074 necrotic cell death Effects 0.000 abstract 2
- 238000002679 ablation Methods 0.000 abstract 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000000315 cryotherapy Methods 0.000 abstract 1
- 238000004520 electroporation Methods 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 238000011293 immunotherapeutic strategy Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/796,171 US9320794B2 (en) | 2006-11-13 | 2013-03-12 | Ablative immunotherapy |
| PCT/US2014/022287 WO2014164396A1 (en) | 2013-03-12 | 2014-03-10 | Ablative immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015022974A2 BR112015022974A2 (pt) | 2017-07-18 |
| BR112015022974A8 true BR112015022974A8 (pt) | 2019-11-26 |
Family
ID=51658863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015022974A BR112015022974A8 (pt) | 2013-03-12 | 2014-03-10 | composição terapêutica para tratar um tumor ou patógeno, composição de vacina e uso |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2970910A4 (ja) |
| JP (1) | JP6538647B2 (ja) |
| KR (1) | KR102265276B1 (ja) |
| CN (2) | CN105102613A (ja) |
| AU (2) | AU2014249374A1 (ja) |
| BR (1) | BR112015022974A8 (ja) |
| CA (1) | CA2904853A1 (ja) |
| IL (1) | IL241326B (ja) |
| PH (1) | PH12015502086A1 (ja) |
| SG (2) | SG10201707446PA (ja) |
| WO (1) | WO2014164396A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110151309B (zh) * | 2018-02-14 | 2022-02-15 | 上海美杰医疗科技有限公司 | 多模态消融治疗术前规划方法及其设备 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| CN1806849A (zh) * | 2005-01-19 | 2006-07-26 | 上海三维生物技术有限公司 | 肿瘤的治疗方法 |
| US20080112963A1 (en) * | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| WO2009095033A1 (en) * | 2008-01-31 | 2009-08-06 | Agirx Limited | Vaccine compositons |
-
2014
- 2014-03-10 EP EP14779681.7A patent/EP2970910A4/en not_active Ceased
- 2014-03-10 JP JP2016500938A patent/JP6538647B2/ja active Active
- 2014-03-10 SG SG10201707446PA patent/SG10201707446PA/en unknown
- 2014-03-10 CN CN201480014494.7A patent/CN105102613A/zh active Pending
- 2014-03-10 WO PCT/US2014/022287 patent/WO2014164396A1/en active Application Filing
- 2014-03-10 BR BR112015022974A patent/BR112015022974A8/pt not_active Application Discontinuation
- 2014-03-10 CA CA2904853A patent/CA2904853A1/en not_active Abandoned
- 2014-03-10 KR KR1020157028277A patent/KR102265276B1/ko active IP Right Grant
- 2014-03-10 SG SG11201507350WA patent/SG11201507350WA/en unknown
- 2014-03-10 CN CN201710016168.5A patent/CN106581673A/zh active Pending
- 2014-03-10 AU AU2014249374A patent/AU2014249374A1/en not_active Abandoned
-
2015
- 2015-09-08 IL IL241326A patent/IL241326B/en active IP Right Grant
- 2015-09-11 PH PH12015502086A patent/PH12015502086A1/en unknown
-
2020
- 2020-02-21 AU AU2020201309A patent/AU2020201309A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015022974A2 (pt) | 2017-07-18 |
| EP2970910A1 (en) | 2016-01-20 |
| CN105102613A (zh) | 2015-11-25 |
| JP2016518319A (ja) | 2016-06-23 |
| CN106581673A (zh) | 2017-04-26 |
| IL241326B (en) | 2021-05-31 |
| PH12015502086A1 (en) | 2016-01-18 |
| EP2970910A4 (en) | 2016-11-16 |
| KR102265276B1 (ko) | 2021-06-16 |
| IL241326A0 (en) | 2015-11-30 |
| WO2014164396A1 (en) | 2014-10-09 |
| JP6538647B2 (ja) | 2019-07-03 |
| AU2020201309A1 (en) | 2020-03-12 |
| CA2904853A1 (en) | 2014-10-09 |
| AU2014249374A1 (en) | 2015-09-24 |
| SG11201507350WA (en) | 2015-10-29 |
| SG10201707446PA (en) | 2017-10-30 |
| KR20150138234A (ko) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hurwitz et al. | Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care | |
| JP6085611B2 (ja) | 癌免疫療法 | |
| BR112015006176A8 (pt) | método de tratamento de câncer em um indivíduo com necessidade de tratamento | |
| MX2018001659A (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| MX2017013142A (es) | Terapia combinada para tratar cáncer. | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| BR112015002706A8 (pt) | Niclosamida e seus derivados para uso no tratamento de tumores sólidos | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| PL2288413T3 (pl) | Urządzenie terapeutyczne łączące radioterapię z termoterapią | |
| WO2013095736A3 (en) | Gold-in-silicon nanoassembly for thermal therapy and methods of use | |
| BR112016013026A2 (pt) | compostos para receptor-3 de fator de crescimento de fibroblasto (fgfr3) e métodos de tratamento | |
| Loi et al. | Thermal Ablation versus SBRT in liver tumours: pros and cons | |
| MX2015006544A (es) | Sulfonamidas con sustitucion biarilo y su uso. | |
| Gao et al. | Radiofrequency ablation does not induce the significant increase of CD4+ CD25+ Foxp3+ regulatory T cells compared with surgical resection in Hepal-6 tumor model | |
| BR112015022974A8 (pt) | composição terapêutica para tratar um tumor ou patógeno, composição de vacina e uso | |
| Chen et al. | Tumor ablation with nanosecond pulsed electric fields | |
| CL2018002438A1 (es) | Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna. | |
| Bristow et al. | The successful use of a novel microwave device in the treatment of a plantar wart | |
| Moghadam et al. | A brief review of Hyperthermia as a neoadjuvant therapy method related to cancer treatment | |
| Song et al. | Doxorubicin hydrochloric increases tumour coagulation and end-point survival in percutaneous microwave ablation of tumours in a VX2 rabbit tumour model | |
| Idrees et al. | A review on potential benefits of hyperthermia in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |